LifeStance Health (LFST) EBIT Margin (2020 - 2026)

LifeStance Health has disclosed EBIT Margin across 7 years of filings, most recently posting 5.52% for Q1 2026.

• In Q1 2026, EBIT Margin rose 504.0% year-over-year to 5.52%; the TTM figure through Mar 2026 stood at 3.0% (up 403.0% YoY), while the FY2025 annual figure was 1.7%, up 422.0% from the prior year.
• EBIT Margin improved to 5.52% in Q1 2026, from 4.73% in the prior quarter.
• Over the last five years, EBIT Margin for LFST reached as high as 40.44% in Q4 2023 and fell as low as 31.93% in Q1 2022.
• The 5-year median for EBIT Margin is 5.11% (2024), against an average of 6.89%.
• Annual changes were most pronounced in 2022 — EBIT Margin plunged 7408 bps — and 2023, when it jumped 6050 bps.
• A 5-year view of EBIT Margin shows it stood at 20.06% in 2022, then soared by 302 bps to 40.44% in 2023, then slumped by 99 bps to 0.33% in 2024, then jumped by 1354 bps to 4.73% in 2025, then rose by 17 bps to 5.52% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 5.52%, 4.73%, and 2.04% for Q1 2026, Q4 2025, and Q3 2025 respectively.